Editor's Pick
Radiopharm Theranostics (RAD:AU) has announced Strategic Co-Development Partnership with Lantheus for Aus Download the PDF here. This post appeared first on investingnews.com
Connect with us
Hi, what are you looking for?
Dividends Growth – Investment and Stock News
- Investing
Trump’s exaggerated claim that Pennsylvania has 500,000 fracking jobs
Tucker Carlson says father Trump will give ‘spanking’ at rowdy Georgia rally
A GOP operative accused a monastery of voter fraud. Nuns fought back.
American creating deepfakes targeting Harris works with Russian intel, documents show
Early voting in Wisconsin slowed by label printing problems
- Stock
Google CEO Pichai struggled to navigate a pressure-filled year
Ad revenue should stabilize for media companies in 2025 — if they have sports
Richard Parsons, former Time Warner CEO, dies at age 76
Treasury delays deadline for small businesses to file new form to avoid noncompliance fines
Digital health companies pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
- Economy
Jimmy Carter ‘killer rabbit attack’ story highlighted his struggles as president
Germany accuses Elon Musk of trying to interfere in its national elections
Trump gives Johnson ‘complete and total endorsement’ ahead of speakership fight
Jimmy Carter nears the top of America’s ‘Most Admired Man’ list, according to Gallup
Uncovering the atrocities of the Assad regime at its ‘death factory’ on the hill
- Editor’s Pick
- Latest News
Three women die after eating Christmas cake in suspected poisoning in Brazil
Iran confirms arrest of Italian journalist, state media reports
Sobbing and prayers echo through South Korean airport as families mourn air crash victims
Germany accuses Elon Musk of trying to influence its election
Israel raid empties northern Gaza’s last functioning major hospital of all patients and detains its director
Editor's Pick
5. Peter Grandich, Peter Grandich & Company Kicking off the list in the fifth spot is Peter Grandich of Peter Grandich & Company. Speaking...
Editor's Pick
As the year closes, we’re taking a look back at our most popular copper news articles of 2024. Copper performed strongly in 2024, setting...
Editor's Pick
As the year closes, we’re taking a look back at our most popular uranium news articles of 2024. The uranium sector has been on...
Editor's Pick
Nordic Nickel Limited (ASX: NNL; Nordic, or the Company) is pleased to announce extremely positive results from its first pass metallurgical testing program for...
Editor's Pick
While momentum began in the east, he now sees the west increasingly turning to gold as a safe haven. ‘I do really think what...
Editor's Pick
Samarco Mineração, along with parent companies Vale (NYSE:VALE) and BHP (ASX:BHP,NYSE:BHP,LSE:BHP), has confirmed ongoing settlement negotiations with Brazilian authorities over the Fundão dam collapse....
Editor's Pick
Hemlock Semiconductor (HSC) is set to enhance its operational capacity in Michigan, US, after the announcement of a preliminary agreement for a US$325 million...
Editor's Pick
IsoEnergy (TSX:ISO,OTCQX:ISENF) and Purepoint Uranium (TSXV:PTU,OTCQB:PTUUF) have formed a joint venture focused on the exploration and development of uranium properties in Saskatchewan’s Athabasca Basin....
Editor's Pick
Quetzal Copper Corp. (TSXV: Q) (‘Quetzal’ or the ‘Company’) is pleased to announce the results from the Annual General Meeting (the ‘Meeting’) held on...
Editor's Pick
Key Assay Highlights: Total Samples Analyzed: 388 rock samples. Titanium Dioxide (TiO2): 49 samples returned assay values over 4.0% TiO2, with a maximum value...
Editor's Pick
IsoEnergy Ltd. (TSX: ISO) (OTCQX: ISENF) (‘IsoEnergy‘) and Purepoint Uranium Group Inc. (TSXV: PTU) (OTCQB: PTUUF) (‘Purepoint’) are pleased to announce that they have...
Editor's Pick
Lode Gold Resources Inc. (TSXV: LOD) (OTCQB: SBMIF) (‘Lode Gold ‘ or the ‘Company’) is pleased to announce its wholly-owned subsidiary, (‘1475039 B.C. Ltd.’...
Editor's Pick
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with...
